MedTrace Logo

Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI

NCT01327534 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2016-06-17

No results posted yet for this study

Summary

Acute myocardial infarction is generally caused by a thrombotic occlusion of coronary arteries. Primary aim of early therapy is a fast and complete reperfusion of the infarcted myocardium.

Conditions

Interventions

DRUG

Prasugrel

treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days

DRUG

Clopidogrel

treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days

Sponsors & Collaborators

  • Daiichi Sankyo

    collaborator INDUSTRY

  • Stiftung Institut fuer Herzinfarktforschung

    lead OTHER

Principal Investigators

  • Uwe Zeymer, MD · Klinikum Ludwigshafen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2013-03-31
Completion
2013-07-31

Countries

  • France
  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01327534 on ClinicalTrials.gov